NCT01295294 - Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA) | Biotech Hunter

Enrollment

187

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Uterine Hemorrhage

Interventions

DRUG

Tranexamic acid

500 mg 3 times daily per oral during bleeding/spotting episodes

DRUG

Mefenamic acid

500 mg 3 times daily per oral during bleeding/spotting episodes

DRUG

Placebo

3 times daily per oral during bleeding/spotting episodes

DRUG

Mirena (Levonorgestrel IUS, BAY86-5028)

In vitro release rate 20 microgram/24 hours. Intrauterine system

Trial Locations (12)

Elverum

Haugesund

Trondheim

Aalborg

Århus C

København NV

Odense C

Skive

Søborg

Mallow

Blackrock

Cork